论文部分内容阅读
目的:观察瑞舒伐他汀联用硫酸氯吡格雷对急性冠脉综合症患者超敏C反应蛋白及血脂的影响。方法:将80例急性冠脉综合症患者分成治疗组(40例)和对照组(40例),治疗组采用瑞舒伐他汀联用硫酸吡格雷治疗,对照组采用常规治疗;治疗8周后观察两组患者血清中超敏C反应蛋白水平和血脂含量变化。结果:治疗组患者治疗8周后血清超敏C反应蛋白和血脂水平均显著下降,与对照组比较,差异有统计学意义(P<0.01)。结论:瑞舒伐他汀联合硫酸吡格雷能明显抑制ACS的炎性反应,显著降低血浆超敏C反应蛋白和血脂水平。
AIM: To observe the effect of rosuvastatin combined with clopidogrel on hypersensitive C-reactive protein and lipids in patients with acute coronary syndrome. Methods: Eighty patients with acute coronary syndrome were divided into treatment group (40 cases) and control group (40 cases). The treatment group was treated with rosuvastatin and pioglitis sulfate, while the control group was treated with conventional therapy. After 8 weeks of treatment, Serum levels of hypersensitive C-reactive protein and blood lipid were observed in two groups. Results: After treatment for 8 weeks, the levels of serum high-sensitivity C-reactive protein and serum lipids were significantly decreased in the treatment group compared with the control group (P <0.01). Conclusion: Rosuvastatin combined with pioglitazone can significantly inhibit the inflammatory response of ACS and significantly reduce the plasma levels of high-sensitivity C-reactive protein and blood lipid.